Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc at Bank of America NAPA Healthcare Conference (Virtual) Transcript

Jun 16, 2021 / 04:30PM GMT
Release Date Price: $38.3 (+4.76%)
Alec Warren Stranahan
BofA Securities, Research Division - Associate

All right. Great. Hey, everyone. Good afternoon, and welcome to Day 3 of our Napa Biopharma Conference. Thanks for joining this session with REGENXBIO. My name is Alec Stranahan, I'm an analyst spearhead. I'm on the U.S. Biopharma team at BofA, and I'm also joined by Geoff Meacham, who is the senior U.S. biopharma analyst at Bank of America.

And we're also pleased to have Ken Mills, President and Chief Executive Officer; as well as Steve Pakola, Chief Medical Officer of REGENXBIO on the line as well. Ken and Steve, thanks for joining us.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Thanks for having us, Alec.

Alec Warren Stranahan
BofA Securities, Research Division - Associate

Perfect. So lots to go through, so maybe we'll just jump straight into Q&A. I have a few here, but for those dialed into the webcast, if you do have questions, feel free to log them via the platform or shoot them over via e-mail.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot